| My Odyssey |
|
|
| Written by Dr. Mel | |||||||||||
| Tuesday, 28 February 2006 | |||||||||||
Page 8 of 9 During these good years, I moved to my dream house on the beach outside of New Haven, and finally bought my dream piano – a Steinway Grand. Why should myeloma stop us from living for today? I always loved music, and I grew up with a nice baby grand. During the 1980s, I was doing well with musical efforts. I was writing quite a bit of jazz and practicing for hours on weekends. But when the myeloma hit, I was forced to stop playing. The pain was too great. Then, within the past year, I did feel well enough to go out and get that piano. I still can only play for a limited time, and I do have those numb hands from neuropathy, but that condition has sort of come in “handy” – it’s the excuse for my less than exceptional performances. Now, all this brings us to this early Sunday morning in late February of 2006. I have noticed some increase in the cancer protein level. The increase is practically infinitesimal, but it is there and giving me some cause for concern. I have had three wonderful years on the combined Revimid(now Revlimid) and Dex therapy. These have truly been the best years of my life. Each day is more precious than the day before. But if the cancer returns, I am ready to reach on that shelf again, and go forward. I know I can. But at the same time, we all realize there has yet to be a cure for this disease, and at best, we can hope to manage it and deal with the drugs and their inevitable side effects. I know Dex can drive you wild, especially at the beginning of some of the treatments when it is taken with great frequency. But at reduced doses given in greater intervals, our insanity is just temporary. |
|||||||||||
| < Prev | Next > |
|---|
Multiple Myeloma News Update
-
Immunomedics to Present At 50th ASH Annual Meeting
GlobeNewsWire (press release), CA - 5 hours ago
... Moscone Center, Hall A) --"First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma" (Publication No. ... -
Xencor to Present New Data from Pre-Clinical Antibody Programs at ...
MarketWatch - 6 hours ago
... XmAb5485, Exhibits Potent Activity In Vitro and In Vivo Against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma," on Tuesday, ... -
The International Myeloma Foundation Says Patient Experience ...
MarketWatch - 6 hours ago
Multiple myeloma is a cancer of cells in the bone marrow that affects blood cell production. It cannot be cured, however new therapies used in combination ... -
InforSense Partners With the UK's South London and Maudsley NHS ...
MarketWatch - 10 hours ago
... research into diseases such as Alzheimer's, breast cancer and multiple myeloma," said Jonathan Sheldon, Chief Scientific Officer at InforSense. ...
InforSense Partners With the UK's South London and Maudsley NHS ... International Business Times
all 13 news articles -
Astex presents updates on AT7519 and AT9283 at the American ...
PharmaLive.com (press release), PA - 20 hours ago
Together, these data provide the rationale for further clinical evaluation of AT7519 in the treatment of multiple myeloma and CLL and suggests that AT7519 ... -
Dec 6, 2008 Monthly meeting of the NE TN Multiple Myeloma Support ...
Kingsport Times News, TN - Nov 30, 2008
By Ellen Barrett The Northeast Tennessee Multiple Myeloma Support Group will have it’s next monthly meeting at the Health Resources Center Annex at the Mall ... -
Multiple Myeloma Research Foundation’s (MMRF) annual gala raises ...
Norwalk Plus Magazine - Nov 25, 2008
By Press Release The Multiple Myeloma Research Foundation (MMRF) raised over $1.5 million at its 12th annual "Friends for Life" Fall Gala held on November 1 ... -

HemOncTodayLast decade brought progress in treatment of multiple myeloma
HemOncToday, NJ - Nov 25, 2008
Major strides have been made in the treatment of multiple myeloma in the last decade, with the advent of new agents such as thalidomide, lenalidomide and ...












